Health & Fitness
Thu, April 5, 2012
DUBLIN, Calif.--([ BUSINESS WIRE ])--Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced the acceptance of fourteen abstracts for presentation at the American Association for Cancer Research (AACR) 2012 Annual Meeting. Oral and poster presentations will occur on March 31, April 1-3 in Chicago, IL.
Highlights include two oral presentations and two poster presentations on SGI-110, Astexas novel second generation DNMT inhibitor, and a poster presentation on new data from the first in class dual IAP inhibitor program:
Saturday, March 31, 2012 | 3:55 a" 4:30 pm CT | SGI-110 | ||
| Invited Presentation | ||||
| Scale-up and development of a process for a low-volume subcutaneous formulation of SGI-110, a potent hypomethylating agent | ||||
Monday, Apr 2, 2012 | 1:00 a" 5:00 pm CT | IAP | ||
| Poster Presentation, Abstract # 2018 | ||||
| Discovery of potent dual inhibitors of both XIAP and cIAP1 using fragment based drug discovery | ||||
Monday, Apr 2, 2012 | 3:00 a" 5:10 pm CT | SGI-110 | ||
| Oral Presentation, Abstract #: LB-214 | ||||
| Interim results from a randomized Phase 1-2 first-in-human-(FIH) study of PK/PD guided escalating doses of SGI-110, a novel subcutaneous (SQ) second generation hypomethylating agent (HMA) in relapsed/refractory MDS and AML | ||||
Tuesday, Apr 3, 2012 | 1:00 a" 5:00 pm CT | SGI-110 | ||
| Poster Presentation, Abstract # 4077 | ||||
| Chemosensitizing effects of the novel, small molecule DNA methylation inhibitor SGI-110 in ovarian cancer | ||||
Tuesday, Apr 3, 2012 | 1:00 a" 5:00 pm CT | SGI-110 | ||
| Poster Presentation, Abstract # 4076 | ||||
| SGI-110, a novel subcutaneous (SQ) second generation DNA hypomethylating agent achieves improved pharmacodynamics (PD), safety and pharmacokinetics (PK) in comparison to IV decitabine in a non-human primate in vivo study | ||||
Nine additional presentations will highlight new data on the companyas drug development programs with AT13387 (HSP90 inhibitor), AT9283 (JAK/Aurora inhibitor), AT13148 (AGC Kinase inhibitor), MetAP2 inhibitors, PKM2 (Pyruvate Kinase) activators, and second generation PIM Kinase inhibitors. Select posters will be made available for viewing on the companyas website [ www.astx.com ] following the public presentation.
About Astex Pharmaceuticals
Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals developed Dacogen (decitabine) for Injection and receives significant royalties on global sales.
For more information about Astex Pharmaceuticals, Inc., please visit [ http://www.astx.com ].
